Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

NCT00473005 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Principal Investigator (Dr. Guardino) left Stanford

Conditions

Breast Cancer

Interventions

DRUG: Capecitabine
DRUG: RAD001

Sponsor

Stanford University

Collaborators

[object Object]